Last reviewed · How we verify
Hunan Kelun Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Etomidate Injectable Emulsion | Etomidate Injectable Emulsion | phase 3 | GABA-A receptor positive allosteric modulator; general anesthetic | GABA-A receptor | Anesthesiology |
Therapeutic area mix
- Anesthesiology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Hunan Kelun Pharmaceutical Co., Ltd.:
- Hunan Kelun Pharmaceutical Co., Ltd. pipeline updates — RSS
- Hunan Kelun Pharmaceutical Co., Ltd. pipeline updates — Atom
- Hunan Kelun Pharmaceutical Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Hunan Kelun Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hunan-kelun-pharmaceutical-co-ltd. Accessed 2026-05-16.